Inovio Pharmaceuticals, Inc.

INONASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
1.30 USD
↗ 0.01 (0.78%)AT CLOSE (11:59 AM EDT)
1.29
↘ 0.02 (1.15%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
1.29
↘ 0.02 (1.15%)
🔴Market: CLOSED

Inovio Pharmaceuticals, Inc. (INO) trades at $1.31 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, INO is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Aug 26, 2026.

Open?$1.28
High?$1.37
Low?$1.25
Prev. Close?$1.29
Volume?3.7M
Avg. Volume?5.1M
VWAP?$1.29
Rel. Volume?0.73x
Bid / Ask
Bid?$1.12 × 100
Ask?$1.49 × 100
Spread?$0.37
Midpoint?$1.31
Valuation & Ratios
Market Cap?133.4M
Shares Out?103.4M
Float?81.0M
Float %?98.5%
P/E Ratio?N/A
P/B Ratio?30.51
EPS?-$0.65
Dividend?0.00%
Ex-Dividend?N/A
RelatedMRNA
News
Profile
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
112
Market Cap
133.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.inovio.com
Listed
1998-12-08
Address
660 W. GERMANTOWN PIKE
PLYMOUTH MEETING, PA 19462
Phone: (858) 410-3134
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
21
Piotroski F-Score?0/9Weak
Altman Z-Score?-55.29Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.64%Squeeze Risk
Short Interest?20.0M
Days to Cover?3.7
Free Float81.0M
Avg Daily Volume5.4M
Settlement Date2026-08-14
Financial Health
Current Ratio?1.00Adequate
Quick Ratio?1.00Adequate
Cash Ratio?0.79Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
50
S&P
3
30.51HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-1,542.6%WEAK▾
ROA?
S&P
3
-136.5%WEAK▾
Cash Flow & Enterprise
FCF?$-80777982
Enterprise Value?$101.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist